ACAD
Acadia Pharmaceuticals Inc

13,120
Mkt Cap
$3.72B
Volume
0.00
52W High
$26.65
52W Low
$13.40
PE Ratio
16.55
ACAD Fundamentals
50D MA
$23.23
Beta
0.99
Avg. Volume
2.34M
EPS (Annual)
$1.36
P/B
4.51
Rev/Employee
$1.46M
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders...
Business Wire·3d ago
News Placeholder
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...
PR Newswire·4d ago
News Placeholder
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets...
Business Wire·10d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·12d ago
News Placeholder
QGEN vs. ACAD: Which Stock Is the Better Value Option?
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Zacks·16d ago
News Placeholder
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Zacks·25d ago
News Placeholder
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Zacks·30d ago
News Placeholder
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.
Stocktwits·1mo ago
News Placeholder
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Zacks·2mo ago

Latest ACAD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.